Retatrutide vs Cagrilintide: Triple Agonist vs Amylin Research Comparison for UAE Labs (2026)

Published 24 June 2026 · REVIVE Peptides Research Desk · 11 min read
TL;DR. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) that produced ~24.2% weight loss at 48 weeks at 12 mg in Jastreboff 2023 NEJM. Cagrilintide is a long-acting amylin analogue that peaked at ~10.8% as monotherapy (Lau 2021) but reaches ~22.7% when combined with semaglutide as CagriSema (REDEFINE-1, Garvey 2025). For UAE research, retatrutide wins on raw monotherapy effect size; cagrilintide shines as a combination partner. REVIVE stocks retatrutide 5/10 mg vials with 24h Dubai delivery and next-day to Abu Dhabi/Sharjah — buy retatrutide UAE 24h delivery here.

Two Very Different Molecules, One Shared Endpoint

Both compounds target body-weight reduction in obesity research, but they get there through completely different receptors. Understanding the mechanism gap is the difference between picking the right tool for a research question and wasting a 24-week protocol.

Retatrutide (LY3437943, Eli Lilly) is a synthetic triple agonist developed by Coskun and colleagues that activates the GLP-1, GIP, and glucagon receptors simultaneously (Coskun 2022). Cagrilintide (AM833, Novo Nordisk) is a long-acting analogue of human amylin, a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. The amylin receptor is a calcitonin-receptor/RAMP heterodimer expressed densely in the area postrema — the brainstem nausea/satiety hub.

This receptor-level divergence drives every downstream difference: dose curves, side-effect profiles, combination logic, and the kind of research question each compound answers best.

Mechanism Side-by-Side

PropertyRetatrutideCagrilintide
ClassTriple incretin agonistAmylin analogue
ReceptorsGLP-1R + GIPR + GCGRAmylin (CTR + RAMP)
Primary CNS targetArcuate nucleus, hypothalamusArea postrema, NTS
Peripheral effectInsulin secretion + energy expenditureSlowed gastric emptying, glucagon suppression
Half-life~6 days~7-8 days (weekly SC)
Studied weight loss (mono)~24.2% at 48 wk (12 mg)~10.8% at 26 wk (2.4 mg)
Key Phase 2 trialJastreboff 2023 NEJMLau 2021 Lancet

Retatrutide's glucagon arm is the unusual feature — most weight-loss research drugs avoid glucagon because of glycemic concerns, but Lilly's structural approach lets the GLP-1 component buffer glucose while glucagon drives lipolysis and energy expenditure. That third receptor is why the dose curve in Jastreboff 2023 keeps descending past 8 mg when GLP-1 monotherapies have already plateaued.

Cagrilintide takes a complementary route: it doesn't push energy expenditure, it crushes hunger signalling through a different brain region than GLP-1. That mechanistic separation is exactly why the CagriSema combination was designed.

CagriSema — The Combination Trial Data

CagriSema is the fixed-ratio combination of cagrilintide 2.4 mg + semaglutide 2.4 mg, weekly SC. The Phase 2 trial (Enebo 2021, Lancet) in type 2 diabetes showed superiority over either component alone. The pivotal REDEFINE-1 Phase 3 trial (Garvey 2025) extended this to non-diabetic obesity:

ArmWeight loss at 68 wkNotes
Placebo~2.3%Lifestyle only
Cagrilintide 2.4 mg mono~11.5%Amylin alone
Semaglutide 2.4 mg mono~16.1%GLP-1 alone
CagriSema 2.4/2.4 mg~22.7%Combination

The combination effect is roughly additive rather than synergistic, but ~22.7% closes most of the gap with retatrutide 12 mg monotherapy at 24.2%. The trade-off is two molecules' worth of side-effect surface area and a more complex injection schedule. For a UAE researcher choosing between a single-molecule triple-agonist or a dual-injection combo, retatrutide's logistical simplicity is a real advantage.

Side-Effect Profile Comparison

For tolerability management in either compound, see our GLP-1 and incretin nausea mitigation protocols — most of the same tactics (evening dosing, low-fat 48h post-injection, ginger, electrolyte loading) work for both classes.

Which Research Question Favors Which Compound?

Pick retatrutide when:

Pick cagrilintide when:

For most UAE labs running general obesity, metabolic syndrome, or MASH research, retatrutide is the default workhorse. Cagrilintide earns its place in studies designed around amylin biology specifically or combination pharmacology.

Buy Retatrutide in the UAE — 24h Delivery to Dubai, Abu Dhabi, Sharjah
REVIVE Peptides stocks retatrutide 5 mg and 10 mg vials in Dubai with HPLC certificates, cold-chain dispatch, and same-day delivery inside Dubai for orders before 2pm.
Order Retatrutide UAE — In Stock Now →

UAE Delivery & Sourcing — Where to Buy Retatrutide in the UAE with 24h Delivery

REVIVE Peptides operates from Dubai with a temperature-controlled warehouse and a dispatch desk covering all seven emirates. Cagrilintide is not currently in our UAE inventory; retatrutide is the in-stock triple-agonist alternative.

EmirateDelivery windowCold-chainCut-off
DubaiSame-dayIce-pack courierOrder by 2pm
Abu DhabiNext-day (24h)Insulated overnightOrder by 5pm
SharjahSame/next-dayIce-pack courierOrder by 3pm
AjmanNext-day (24h)Insulated overnightOrder by 5pm
Ras Al Khaimah24-48hInsulated overnightOrder by 4pm
Fujairah / UAQ48hInsulated overnightOrder by 4pm

Cold-chain logistics. Lyophilised retatrutide is stable at 2-8 degC; in UAE summer ambient (45 degC+) the dispatch protocol uses pre-conditioned gel packs in expanded-polystyrene insulated boxes rated for 24-36 hours of thermal protection. Sealed lyo vials tolerate brief room-temperature exposure but cold-chain is non-negotiable for inter-emirate dispatch in July-September.

REVIVE Dubai stock. Current inventory: Retatrutide 5 mg and 10 mg, Tesamorelin 5/10 mg, GHK-Cu 50/100 mg, BPC-157 5 mg, TB-500 5 mg, MOTS-c 10 mg, Semax 10 mg, NAD+ 100 mg, and Bacteriostatic Water 3 mL. Each retatrutide batch ships with a third-party HPLC purity certificate.

Ordering process. Place the order via the retatrutide product page, complete checkout, and receive a dispatch confirmation with courier tracking. Same-day Dubai orders are typically delivered between 4pm and 9pm. For bulk orders or research-grade quantities, the UAE peptide catalogue page lists volume pricing.

Research use only. All peptides supplied by REVIVE Peptides UAE are labelled and sold strictly for in-vitro and research purposes — not for human consumption, not for therapeutic or diagnostic use, and not approved by the UAE Ministry of Health or any other regulatory authority for clinical application.

Cost-Per-Endpoint — Practical Research Economics

Per Drucker 2024 and Müller 2019 review work, cost-per-percent-weight-loss is a fair way to compare incretin and amylin research compounds across a 24-week protocol. Retatrutide's wider dose range (0.5-12 mg) lets a single 10 mg vial cover roughly 20 weeks at a 0.5 mg starting dose, or 2.5 weeks at 4 mg. Cagrilintide protocols typically run 0.3-2.4 mg, so vial economics are similar at maintenance doses. For combination protocols (CagriSema model) you double the spend.

For step-by-step reconstitution see our retatrutide reconstitution math guide; for the 24-week dose escalation see the retatrutide titration schedule UAE.

Bottom Line for UAE Researchers

If you are running a single-molecule obesity or MASH study and want maximum effect-size headroom plus simple weekly dosing, retatrutide is the cleaner choice — and it is the one REVIVE actually stocks in Dubai for 24h delivery. If your protocol specifically dissects amylin biology or replicates the CagriSema combination, cagrilintide has its place, but you will source it elsewhere and accept a longer lead time.

For most labs we work with across Dubai, Abu Dhabi, and Sharjah, the practical answer is to buy retatrutide UAE 24h delivery from REVIVE and reserve cagrilintide procurement for combination-specific projects.

References

  1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
  2. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234-1247.
  3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.
  4. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
  5. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748.
  6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
  7. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.
  8. Muller TD, Bluher M, Tschop MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223.
  9. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311-319.
  10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.